drugset

drugset / Trial / NCT01588145

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

NCT01588145 ↗

Phase 1/2 Completed 273 enrolled Hanmi Pharmaceutical Company Limited

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the safety and tolerability of HM61713.

Timeline

Start: 2012-03
Primary completion: 2017-08
Completion: 2017-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olmutinib	Small molecule	—	Oral

Indications